Mandy Juarez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mandy Juarez has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Schcolnik-Cabrera
Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada
2 shared publications - Alma Chavez-Blanco
Division of Basic Research, National Institute of Oncology, Mexico City, Mexico
2 shared publications - Ariana Vargas-Castillo
Department of Cancer Biology, Dana Farber Cancer Institute, Boston, USA
2 shared publications - Armando R. Tovar
Departamento de Fisiología de la Nutrición, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2 shared publications - Joshua Ayork Acevedo-Carabantes
Nutrition Physiology Department, National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, Mexico
2 shared publications - Lilia-Guadalupe Noriega
Departamento de Fisiología de la Nutrición, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
2 shared publications
Latest Publications
- 14 March 2025
- Published by Elsevier in Life Sciences
- Vol. 370, 123562
Metabolic reprogramming and synergistic cytotoxicity of genistein and chemotherapy in human breast cancer cells
- 14 March 2025
- Published by Elsevier in Life Sciences
- Vol. 370, 123562
Metabolic reprogramming and synergistic cytotoxicity of genistein and chemotherapy in human breast cancer cells
- Open Access
Metabolic reprogramming and synergistic cytotoxicity of genistein and chemotherapy in human breast cancer cells
Breast cancer (BCa) is a heterogeneous disease, initially responsive to hormone therapy but often developing resistance to both hormonal and chemotherapy treatments. Novel therapeutic strategies are needed for drug-resistant BCa. Genistein, a phytoestrogen structurally similar to estrogen, competes with estrogen for receptor binding and exhibits anti-cancer effects. In this study, we investigated the cellular and metabolic impacts of genistein, alone or in combination with chemotherapy, in two human BCa cell lines—one estrogen receptor-positive (ER+) and one estrogen receptor-negative (ER−). We observed a strong synergistic effect on cell viability at low concentrations of genistein and chemotherapy, resulting in reduced clonogenic capacity and impaired cell migration. Genistein alone modulated cellular energy metabolism, notably reducing ATP production in MCF7 (ER+) cells. This metabolic shift was linked to a decreased dependence on fatty acids for energy, coupled with a decrease in the rate-limiting mitochondrial translocase CPT1 required for fatty acid oxidation, alongside with an increase in intracellular fatty acid levels. While the most significant changes occurred in ER+ cells, ER− cells also showed responses to genistein treatment. Collectively, our findings suggest that low dose genistein, in combination with conventional chemotherapy, induces synergistic anti-cancer effects, promoting cellular senescence. This effect may be partly mediated by a reduced reliance on fatty acid metabolism in BCa cells.
Open AccessMetabolic reprogramming and synergistic cytotoxicity of genistein and chemotherapy in human breast cancer cells
Breast cancer (BCa) is a heterogeneous disease, initially responsive to hormone therapy but often developing resistance to both hormonal and chemotherapy treatments. Novel therapeutic strategies are needed for drug-resistant BCa. Genistein, a phytoestrogen structurally similar to estrogen, competes with estrogen for receptor binding and exhibits anti-cancer effects. In this study, we investigated the cellular and metabolic impacts of genistein, alone or in combination with chemotherapy, in two human BCa cell lines—one estrogen receptor-positive (ER+) and one estrogen receptor-negative (ER−). We observed a strong synergistic effect on cell viability at low concentrations of genistein and chemotherapy, resulting in reduced clonogenic capacity and impaired cell migration. Genistein alone modulated cellular energy metabolism, notably reducing ATP production in MCF7 (ER+) cells. This metabolic shift was linked to a decreased dependence on fatty acids for energy, coupled with a decrease in the rate-limiting mitochondrial translocase CPT1 required for fatty acid oxidation, alongside with an increase in intracellular fatty acid levels. While the most significant changes occurred in ER+ cells, ER− cells also showed responses to genistein treatment. Collectively, our findings suggest that low dose genistein, in combination with conventional chemotherapy, induces synergistic anti-cancer effects, promoting cellular senescence. This effect may be partly mediated by a reduced reliance on fatty acid metabolism in BCa cells.